New study tailors amyloidosis therapy based on genetic marker
NCT ID NCT06192979
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study tests a personalized approach for people with AL amyloidosis who have a specific genetic change called t(11;14). All 41 participants start with a standard three-drug combination. If their blood responds quickly within a week, they continue that treatment; if not, they switch to a different combination that includes a targeted drug. The goal is to improve the chance of complete blood remission and organ function at 6 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital
RECRUITINGBeijing, Beijing Municipality, 101118, China
-
Capital Medical University Affiliated Fuxing Hospital
RECRUITINGBeijing, Beijing Municipality, 100045, China
-
Chinese PLA Eastern Theater General Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
-
Qilu Hospital of Shandong University (QingDao)
RECRUITINGQingdao, Shandong, 266000, China
-
Qingdao Municipal Hospital
RECRUITINGQingdao, Shandong, 266011, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
RECRUITINGXi’an, Shanxi, 710061, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
- Can a radioactive peptide spot hidden amyloid in the heart?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Nationwide registry aims to crack the code of a rare protein-clogging disease
- New scan spots hidden organ damage before symptoms start
- Could a simple scan unlock better heart treatment?